MeiraGTx Holdings PLC
$ 13.07
2.19%
07 Aug - close price
- Market Cap 1,210,406,000 USD
- Current Price $ 13.07
- High / Low $ 13.11 / 12.70
- Stock P/E N/A
- Book Value -0.71
- EPS -1.48
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -3.68 %
- 52 Week High 15.35
- 52 Week Low 6.62
About
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
Analyst Target Price
$29.29
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-26 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-13 | 2024-11-13 | 2024-08-12 | 2024-05-09 | 2024-03-14 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.57 | 0.19 | -0.62 | -0.48 | -0.51 | -0.5 | -0.55 | -0.76 | -0.77 | -0.42 | -0.74 | -0.53 |
| Estimated EPS | -0.45 | -0.564 | -0.49 | -0.47 | -0.49 | -0.56 | -0.52 | -0.4 | -0.41 | -0.11 | -0.55 | -0.56 |
| Surprise | -0.12 | 0.754 | -0.13 | -0.01 | -0.02 | 0.06 | -0.03 | -0.36 | -0.36 | -0.31 | -0.19 | 0.03 |
| Surprise Percentage | -26.6667% | 133.6879% | -26.5306% | -2.1277% | -4.0816% | 10.7143% | -5.7692% | -90% | -87.8049% | -281.8182% | -34.5455% | 5.3571% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.39 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGTX
2026-08-07 13:40:40
MeiraGTx Holdings PLC (MGTX) has an earnings forecast score of 8.50, ranking 108th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $27.00 for MGTX, with a "Buy" trend based on ratings from 7 analysts. The company's expected revenue for the next quarter is $12.48 million, and EPS for the next quarter is anticipated to be -$0.46.
2026-08-07 03:40:40
MeiraGTx has granted a new hire 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) under its 2026 Employment Inducement Award Plan. The stock options are priced at the Nasdaq closing price on the employee's start date and vest over four years, while the RSUs also vest over four years with specific percentages at two, three, and four years. This move is designed to incentivize and retain the new employee.
2026-08-06 20:39:56
MeiraGTx Holdings plc announced that its Compensation Committee approved equity awards for a new employee. These awards, consisting of non-qualified stock options and time-based restricted stock units, were granted as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are subject to vesting schedules tied to continued employment.
2026-08-06 20:39:56
MeiraGTx (Nasdaq: MGTX) announced that its Compensation Committee approved an inducement grant of 75,000 non-qualified stock options and 75,000 time-based Restricted Stock Units (RSUs) for a new employee. These awards, made under Nasdaq Listing Rule 5635(c)(4), are contingent on continued employment, with specific vesting schedules over one to four years. The stock options' exercise price will be the closing price of MeiraGTx ordinary shares on the employee's start date.
2026-08-03 18:40:40
The article provides an overview of analyst recommendations and price targets for MeiraGTx Holdings PLC (328.SG). It lists several recent analyst actions, including RBC Capital and HC Wainwright & Co. maintaining "Outperform" and "Buy" ratings respectively. The stock currently trades at 11.10 EUR with no change, as of the latest market data.
2026-08-01 02:40:24
MeiraGTx Holdings (MGTX) is a clinical-stage genetic medicines company with a market cap of US$1.1 billion. The company faces financial risks including negative shareholder equity, unprofitability, and past shareholder dilution, though revenue is forecast to grow significantly. Recent developments include a $400 million financing package to accelerate its gene therapy pipeline, positive clinical trial data for AAV-hAQP1 in radiation-induced xerostomia, and FDA Regenerative Medicine Advanced Therapy (RMAT) designations for AAV-GAD and AAV2-hAQP1.
